News Conference News SCAI 2023 SPIRIT 48: Long DES for Diffuse CAD Highly Deliverable, Safe at 1 Year L.A. McKeown May 31, 2023
News Conference News SCAI 2023 Thrombotic Risk Criteria Post-PCI for NSTE ACS Validated in New Analysis L.A. McKeown May 30, 2023
News Conference News EAS 2023 Newest Resorbable Magnesium Scaffold Shows Promise in BIOMAG-1 Michael O'Riordan May 25, 2023
News Conference News SCAI 2023 Repeat Revascularization Not Increased With Solo Ticagrelor: TWILIGHT Analysis L.A. McKeown May 22, 2023
Presentation EuroPCR 2023 BIOADAPTOR RCT: Randomized Controlled Trial of Sirolimus-Eluting Bioadaptor Scaffold Versus Zotarolimus-Eluting Drug-Eluting Stent Presenter: Shigeru Saito May 18, 2023
News Conference News EuroPCR 2023 ‘Fascinating’ Unlocking Coronary Stent Prompts Cautious Praise Michael O'Riordan May 18, 2023
News Daily News Physiologic Testing May ID Patients Who’ll Still Have Angina After PCI Michael O'Riordan March 31, 2023
News Daily News PROMISE II: Flow-Diverting Procedure May Save Limbs in CLTI L.A. McKeown March 29, 2023
News Conference News ACC 2023 No Downside to Immediate Complete Revascularization in ACS: BIOVASC Michael O'Riordan March 06, 2023
News Conference News ACC 2023 Clear CVD Benefit With Bempedoic Acid: CLEAR Outcomes Michael O'Riordan March 04, 2023
News Daily News CT Angiography Is Increasing in England, but Downstream Tests Are Not Michael O'Riordan January 12, 2023
News Opinion Editor's Corner TCTMD’s Top 10 Most Popular Stories for December 2022 Shelley Wood January 03, 2023
News Daily News Anatomic Disease After PCI Linked With Worse Outcomes: VA CART Michael O'Riordan December 22, 2022
News Conference News Paclitaxel Safety Concerns Wane as Hope Emerges for Newer PAD Devices L.A. McKeown November 18, 2022
News Daily News Many STEMI Patients Not Treated Within National Time Goals Michael O'Riordan November 15, 2022
News Conference News AHA 2022 Long-Awaited BEST-CLI Results Favor Surgery Over Endovascular Therapy in CLTI L.A. McKeown November 07, 2022
News Conference News VIVA 2022 TRANSCEND: Low-Dose DCB for PAD Still Looking Good at 2 Years L.A. McKeown November 03, 2022